Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

NPS Pharm., Inc

Article Abstract:

A comparative analysis of the company sales and financial details of NPS Pharmaceuticals, Inc. from 1994 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.

Author: Lewittes, William C.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
Pharmaceutical preparations, NPS Pharmaceuticals Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Pharma Product Development Inc

Article Abstract:

Pharmaceutical Products Development Inc. is expected to earn share net both in 2003 and 2004. Issue is timely offering 3-5 year appreciation potential.

Author: Butler, Jeremy J.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Forecasts, trends, outlooks, Financial management, Labor Distribution by Employer, Finance, Company investment, Investments, Statistics, Pharmaceutical Product Development Inc., PPDI, Company business forecast/projection, Company forecasts

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: United States, Pharmaceutical industry, Securities, Company sales and earnings, Company earnings/profit, Company securities
Similar abstracts:
  • Abstracts: ISIS Pharm., Inc. Vertex Pharmaceuticals Inc
  • Abstracts: Biotechnology industry. Millenium Pharmaceuticals Inc
  • Abstracts: Myriad Genetics. Neurocrine Biosciences Inc
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.